George E Nelson1, Tracy Pondo2, Karrie-Ann Toews2, Monica M Farley3, Mary Lou Lindegren4, Ruth Lynfield5, Deborah Aragon6, Shelley M Zansky7, James P Watt8, Paul R Cieslak9, Kathy Angeles10, Lee H Harrison11, Susan Petit12, Bernard Beall2, Chris A Van Beneden2. 1. Epidemic Intelligence Service National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention Vanderbilt University, Nashville, Tennessee. 2. National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention. 3. Emory University School of Medicine and the VA Medical Center, Atlanta, Georgia. 4. Vanderbilt University, Nashville, Tennessee. 5. Minnesota Department of Health, St Paul. 6. Colorado Department of Public Health and Environment, Denver. 7. New York State Department of Health, Albany. 8. California Department of Public Health, Richmond. 9. Oregon Health Authority, Portland. 10. New Mexico Emerging Infections Program, University of New Mexico, Las Cruces. 11. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 12. Connecticut Department of Public Health, Hartford.
Abstract
BACKGROUND: Invasive group A Streptococcus (GAS) infections are associated with significant morbidity and mortality rates. We report the epidemiology and trends of invasive GAS over 8 years of surveillance. METHODS: From January 2005 through December 2012, we collected data from the Centers for Disease Control and Prevention's Active Bacterial Core surveillance, a population-based network of 10 geographically diverse US sites (2012 population, 32.8 million). We defined invasive GAS as isolation of GAS from a normally sterile site or from a wound in a patient with necrotizing fasciitis (NF) or streptococcal toxic shock syndrome (STSS). Available isolates were emm typed. We calculated rates and made age- and race-adjusted national projections using census data. RESULTS: We identified 9557 cases (3.8 cases per 100 000 persons per year) with 1116 deaths (case-fatality rate, 11.7%). The case-fatality rates for septic shock, STSS, and NF were 45%, 38%, and 29%, respectively. The annual incidence was highest among persons aged ≥65 years (9.4/100 000) or <1 year (5.3) and among blacks (4.7/100 000). National rates remained steady over 8 years of surveillance. Factors independently associated with death included increasing age, residence in a nursing home, recent surgery, septic shock, NF, meningitis, isolated bacteremia, pneumonia, emm type 1 or 3, and underlying chronic illness or immunosuppression. An estimated 10 649-13 434 cases of invasive GAS infections occur in the United States annually, resulting in 1136-1607 deaths. In a 30-valent M-protein vaccine, emm types accounted for 91% of isolates. CONCLUSIONS: The burden of invasive GAS infection in the United States remains substantial. Vaccines under development could have a considerable public health impact.
BACKGROUND: Invasive group A Streptococcus (GAS) infections are associated with significant morbidity and mortality rates. We report the epidemiology and trends of invasive GAS over 8 years of surveillance. METHODS: From January 2005 through December 2012, we collected data from the Centers for Disease Control and Prevention's Active Bacterial Core surveillance, a population-based network of 10 geographically diverse US sites (2012 population, 32.8 million). We defined invasive GAS as isolation of GAS from a normally sterile site or from a wound in a patient with necrotizing fasciitis (NF) or streptococcal toxic shock syndrome (STSS). Available isolates were emm typed. We calculated rates and made age- and race-adjusted national projections using census data. RESULTS: We identified 9557 cases (3.8 cases per 100 000 persons per year) with 1116 deaths (case-fatality rate, 11.7%). The case-fatality rates for septic shock, STSS, and NF were 45%, 38%, and 29%, respectively. The annual incidence was highest among persons aged ≥65 years (9.4/100 000) or <1 year (5.3) and among blacks (4.7/100 000). National rates remained steady over 8 years of surveillance. Factors independently associated with death included increasing age, residence in a nursing home, recent surgery, septic shock, NF, meningitis, isolated bacteremia, pneumonia, emm type 1 or 3, and underlying chronic illness or immunosuppression. An estimated 10 649-13 434 cases of invasive GAS infections occur in the United States annually, resulting in 1136-1607 deaths. In a 30-valent M-protein vaccine, emm types accounted for 91% of isolates. CONCLUSIONS: The burden of invasive GAS infection in the United States remains substantial. Vaccines under development could have a considerable public health impact.
Authors: Mary C Hu; Michael A Walls; Steven D Stroop; Mark A Reddish; Bernard Beall; James B Dale Journal: Infect Immun Date: 2002-04 Impact factor: 3.441
Authors: B J M Vlaminckx; W van Pelt; L M Schouls; A van Silfhout; E M Mascini; C P Elzenaar; T Fernandes; A Bosman; J F P Schellekens Journal: Clin Microbiol Infect Date: 2005-03 Impact factor: 8.067
Authors: L B Olafsdottir; H Erlendsdóttir; J Melo-Cristino; D M Weinberger; M Ramirez; K G Kristinsson; M Gottfredsson Journal: Euro Surveill Date: 2014-05-01
Authors: Deborah A Williamson; Julie Morgan; Virginia Hope; John D Fraser; Nicole J Moreland; Thomas Proft; Graham Mackereth; Diana Lennon; Michael G Baker; Philip E Carter Journal: J Infect Date: 2014-09-20 Impact factor: 6.072
Authors: Michael C Thigpen; Chesley L Richards; Ruth Lynfield; Nancy L Barrett; Lee H Harrison; Kathryn E Arnold; Arthur Reingold; Nancy M Bennett; Allen S Craig; Ken Gershman; Paul R Cieslak; Paige Lewis; Carolyn M Greene; Bernard Beall; Chris A Van Beneden Journal: Emerg Infect Dis Date: 2007-12 Impact factor: 6.883
Authors: Anthony R Flores; Randall J Olsen; Concepcion Cantu; Kyler B Pallister; Fermin E Guerra; Jovanka M Voyich; James M Musser Journal: Infect Immun Date: 2017-04-21 Impact factor: 3.441
Authors: Pierre R Smeesters; Delphine Laho; Bernard Beall; Andrew C Steer; Chris A Van Beneden Journal: Clin Infect Dis Date: 2017-03-01 Impact factor: 9.079
Authors: Holly M Biggs; Chris A Van Beneden; Katie Kurkjian; Miwako Kobayashi; Teresa C T Peret; John T Watson; Eileen Schneider; Susan I Gerber; Jayashree Ravishankar Journal: Clin Infect Dis Date: 2020-06-10 Impact factor: 9.079
Authors: Srinivas Acharya Nanduri; Susan Petit; Chad Smelser; Mirasol Apostol; Nisha B Alden; Lee H Harrison; Ruth Lynfield; Paula S Vagnone; Kari Burzlaff; Nancy L Spina; Elizabeth M Dufort; William Schaffner; Ann R Thomas; Monica M Farley; Jennifer H Jain; Tracy Pondo; Lesley McGee; Bernard W Beall; Stephanie J Schrag Journal: JAMA Pediatr Date: 2019-03-01 Impact factor: 16.193
Authors: Mary Lou Lindegren; Leigh McCormack; Brenda Barnes; Ed Mitchel; Stephen Jones; William Schaffner Journal: Public Health Rep Date: 2016 Jul-Aug Impact factor: 2.792